Femasys (FEMY) to Release Quarterly Earnings on Thursday

Femasys (NASDAQ:FEMY) is anticipated to issue its quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). Femasys had a negative net margin of 1,242.06% and a negative return on equity of 392.45%. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $1.14 million. On average, analysts expect Femasys to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Femasys Trading Down 3.8%

NASDAQ FEMY opened at $0.93 on Thursday. Femasys has a 12 month low of $0.69 and a 12 month high of $1.80. The company has a current ratio of 0.93, a quick ratio of 0.54 and a debt-to-equity ratio of 0.02. The stock’s fifty day moving average price is $0.89 and its 200-day moving average price is $1.15. The stock has a market cap of $30.32 million, a P/E ratio of -1.02 and a beta of -2.58.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Femasys in a research report on Wednesday, June 25th. Jones Trading dropped their target price on shares of Femasys from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.